Yumanity Therapeutics

Overview

Yumanity Therapeutics was an American biotechnology company focused on developing treatments for neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis). The company was founded in 2012 and headquartered in Boston, Massachusetts.

Overview

Yumanity Therapeutics was an American biotechnology company focused on developing treatments for neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis). The company was founded in 2012 and headquartered in Boston, Massachusetts.

Yumanity developed a novel platform targeting protein misfolding and aggregation, a common mechanism underlying many neurodegenerative diseases. The company leveraged innovative approaches to identify small molecules that could prevent or reverse toxic protein aggregation, potentially slowing or halting disease progression["@protein-aggregation"].

Note: Yumanity filed for Chapter 11 bankruptcy in 2022 and its assets were acquired. The company's research contributions remain significant in the field of neurodegenerative disease drug discovery.

Company History

Founding and Scientific Origins (2012-2015)

Yumanity Therapeutics was founded in 2012 by Dr. Michael K. Ahlijanian (CEO) and Dr. Susan L. Lindquist (scientific founder), a renowned scientist from the Whitehead Institute for Biomedical Research at MIT[@lindquist].

The Lindquist Lab Connection

• Alpha-synuclein toxicity in Parkinson's disease[@alpha-synuclein]
• Tau protein aggregation in Alzheimer's disease
• TDP-43 aggregation in ALS
• Huntingtin protein toxicity in Huntington's disease

Platform Development

• Yeast-based screening: Using genetically engineered yeast to model protein aggregation
• Patient-derived iPSCs: Induced pluripotent stem cell models from patients
• Computational chemistry: Structure-based drug design
• Novel target identification: Discovering new biological targets

Growth and Development (2015-2018)

During this period, Yumanity:

• Expanded its scientific team with experts in neurodegeneration, medicinal chemistry, and drug development
• Advanced multiple drug candidates through preclinical development
• Established pharmaceutical partnerships
• Raised significant venture capital funding

Public Offering (2018)

Yumanity went public in 2018, listing on NASDAQ (NASDAQ: YMTX). The IPO provided capital to advance clinical development but also increased pressure to deliver clinical results.

Decline and Bankruptcy (2020-2022)

Despite ambitious development plans, Yumanity faced challenges:

• Clinical trial delays
• Shifting regulatory landscape
• Funding constraints in the biotech sector

Company Overview

| Attribute | Details |
|-----------|---------|
| Headquarters | Boston, Massachusetts, USA |
| Founded | 2012 |
| Founded by | Dr. Michael K. Ahlijanian, Dr. Susan L. Lindquist |
| Public Listing | NASDAQ: YMTX (2018-2022) |
| Status | Filed Chapter 11 (2022), assets acquired |
| Focus | Neurodegenerative disease drug discovery |

Research Platform

Yeast-Based Drug Discovery

Yumanity's core platform utilized yeast models of neurodegeneration:

Platform Advantages

• Rapid screening: Ability to screen thousands of compounds quickly
• Genetic tractability: Easy manipulation of yeast genes
• Conservation: Many disease mechanisms conserved from yeast to humans
• Cost-effective: Lower cost than mammalian screening systems

Disease Models

• α-Synuclein models: For Parkinson's disease drug discovery
• Tau models: For Alzheimer's disease
• TDP-43 models: For ALS
• Huntingtin models: For Huntington's disease[@neurodegeneration-models]

Target Discovery

The platform enabled identification of novel drug targets:

Protein Homeostasis

• Chaperone proteins involved in protein folding
• Protein degradation pathways (autophagy, ubiquitin-proteasome)
• ER stress response mechanisms

Membrane Biology

• STEAP (Six-Transmembrane Epithelial Antigen of the Prostate) family proteins[@steap]
• Membrane lipid composition effects on protein aggregation

Small Molecule Program

Yumanity focused on developing brain-penetrant small molecules:

Drug-like Properties

• Blood-brain barrier penetration
• Oral bioavailability
• Acceptable pharmacokinetics
• Safety for chronic dosing

Mechanism of Action

• Inhibition of protein aggregation
• Modulation of protein homeostasis
• Reduction of toxic oligomer formation

Pipeline Programs

YTX-7739: Parkinson's Disease

YTX-7739 was Yumanity's lead clinical program for Parkinson's disease[@ytx-7739]:

Target

• MSTE20: A novel target in the STEAP family (Six-Transmembrane Epithelial Antigen of the Prostate 20)
• Originally thought to be a metalloreductase involved in iron metabolism
• Later validated as important for alpha-synuclein toxicity

Development Status

• Discovery: Identified through yeast screening platform
• Preclinical: Completed IND-enabling studies
• Phase 1: Entered clinical testing
• Post-acquisition: Discontinued following asset acquisition

Clinical Trial Design

• Phase 1: Single ascending dose, multiple ascending dose in healthy volunteers
• Phase 2: Planned Parkinson's disease patients
• Endpoints: Safety, tolerability, pharmacokinetics, biomarkers

YTX-9184: Parkinson's Disease

YTX-9184 was a backup program targeting [alpha-synuclein](/proteins/alpha-synuclein)[@alpha-synuclein]:

Mechanism

• Direct inhibition of alpha-synuclein aggregation
• Prevention of toxic oligomer formation

Development Status

• Preclinical development
• Discontinued following company closure

Additional Programs

Yumanity had early-stage programs targeting:

• Alzheimer's disease: Tau aggregation inhibitors
• ALS: TDP-43 aggregation inhibitors
• Huntington's disease: Huntingtin protein modulators

Scientific Publications

Yumanity scientists contributed to the scientific literature:

Key Publications

Conference Presentations

• American Academy of Neurology (AAN) annual meetings
• Society for Neuroscience (SfN) meetings
• [World Parkinson Congress](/events/world-parkinson-congress)
• Alzheimer's Association International Conference (AAIC)

Research Contributions

Despite company failure, Yumanity's research contributed to the field:

Novel Target Validation

• Established MSTE20/STEAP3 as a valid drug target for PD
• Demonstrated role of iron metabolism in alpha-synuclein toxicity

Platform Development

• Advanced yeast-based drug discovery for neurodegeneration
• Created workflow from yeast screening to clinical candidates

Training and Expertise

• Trained a generation of scientists in neurodegeneration drug discovery
• Developed expertise in protein aggregation mechanisms

Partnership and Collaborations

Academic Partnerships

• Whitehead Institute for Biomedical Research
• [Massachusetts General Hospital](/institutions/mass-general)
• [University of Pennsylvania](/institutions/university-pennsylvania)
• Parkinson's disease research centers

Pharmaceutical Partnerships

• Discovery collaborations with major pharmaceutical companies
• Data sharing agreements for target validation

Funding

• Multiple venture capital rounds
• NIH research grants
• Foundation support for specific programs

Competitive Landscape

Yumanity competed in the neurodegenerative disease drug development space:

Direct Competitors

• AC Immune: Tau and alpha-synuclein antibodies
• Prothelia: Synuclein aggregation inhibitors
• Neuropore: Protein aggregation inhibitors
• AriBio: Alpha-synuclein targeting programs

Indirect Competition

• Biogen, Eli Lilly, Roche in Alzheimer's
• AbbVie, Roche, Pfizer in Parkinson's
• Cytokinetics, Potential Therapeutics in ALS

Competitive Differentiation

• Novel mechanism (MSTE20 target)
• Yeast-based discovery platform
• Focus on protein aggregation

Financial History

Funding Rounds

Stock Performance

• IPO price: $15/share
• Peak price: ~$25/share (2019)
• Final price before delisting: <$1/share

Legacy and Impact

Although Yumanity is no longer an operating company, its legacy includes:

Post-Acquisition Status

Following the 2022 bankruptcy:

• YTX-7739 program discontinued
• Some assets acquired by other biotechnology companies
• Research materials and data made available to academic collaborators
• No current clinical development of Yumanity programs

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Protein Aggregation Inhibitors](/therapeutics/protein-aggregation-inhibitors)
• [Biotechnology Companies](/companies/biotechnology-companies)
• [Neurodegeneration Drug Development](/topics/neurodegeneration-drug-development)

External Links

• [Yumanity Therapeutics (historical)](https://www.yumanity.com/)
• [PubMed - Protein Aggregation](https://pubmed.ncbi.nlm.nih.gov/?term=protein+aggregation+neurodegeneration)
• [PubMed - Alpha-Synuclein](https://pubmed.ncbi.nlm.nih.gov/?term=alpha-synuclein+parkinson)
• [PubMed - STEAP Proteins](https://pubmed.ncbi.nlm.nih.gov/?term=STEAP+neurodegeneration)
• [Whitehead Institute](https://whitehead.mit.edu/)

References